Product Code: RP-ID-10116989 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10116989
Market Overview:
Anticholinergic Drugs Market Segmentation by Product Type (Natural, Semi-Synthetic Compound, and Synthetic Compound); by Route of Administration (Parenteral, Topical, and Oral); by Application (Muscle Spasm, Parkinson’s Disease, Irritable Bowel Syndrome, Chronic Obstructive Pulmonary Disease, and Overactive Bladder); and by Channel of Distribution (Hospitals, Retail Pharmacies, and Online Pharmacies)-Global Demand Analysis & Opportunity Outlook 2031
Global Anticholinergic Drugs Market Highlights Over 2022 - 2031
The global anticholinergic drugs market generated an approximate revenue figure of USD 6.2 billion in the year 2021 and is anticipated to grow at a CAGR of ~6% over the forecast period, i.e., 2022 – 2031. The growth of the market can be majorly attributed to the growing number of geriatric populations around the world which is also a major base for the rising prevalence of numerous chronic diseases. According to World Population Prospects 2019 given by the United Nations, 1 in 11 people are aged over 65 years as of 2019 and it is projected that 1 in 6 people will be aged over 65 years by the year 2050. Furthermore, extensive investments by government and private companies in the field of life science is expected to be another major factor adding to the market growth. Additionally, the expansion and development of healthcare infrastructure along with twenty-four hours medical assistance are the factors expected to boost the growth of the market.
CLICK TO DOWNLOAD A SAMPLE REPORT
Anticholinergic drugs are used to block acetylcholine-induced neurotransmission in several areas of the body, including the heart, peripheral nervous system, and other body parts. Acetylcholine is a neurotransmitter that regulates involuntary activities such as salivation, perspiration, digestion, and a variety of other such issues. The medication is used to treat a variety of chronic diseases and abnormalities caused by a nervous system including bladder overactivity, pulmonary disease disorder, and irritable bowel syndrome among others.
The global anticholinergic drugs market is segmented by product type, route of administration, application, and by channel of distribution. Based on the product type segment, the market is further divided into natural, semi-synthetic compound, and synthetic compound. The semi-synthetic compound segment is anticipated to hold the largest market size in value and is estimated to grow at a moderate CAGR during the forecast period. The growth of the segment can be associated with the growing use of semi-synthetic compounds for the treatment of spasms or conditions with disturbances in the bladder or gastrointestinal motility. Additionally, they are also administered to treat functional gastrointestinal disorders which is expected to add in the segment growth.
Global Anticholinergic Drugs Market Regional Synopsis
Regionally, the global anticholinergic drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America held the highest market share of anticholinergic drugs market and is anticipated to continue leading the market growth with a significant CAGR during the forecast period. The growth of the market can be attributed to the growing patients suffering from diseases such as Parkinson’s disease, hypertension, and others, along with developed healthcare infrastructure, and better life science research opportunities offered in the region. As a result of being technologically sound, the innovation and development of drugs are more hassle-free which is another major reason expected to drive market growth. According to the Parkinson’s Foundation, nearly 60,000 natives of America are diagnosed with Parkinson’s disease every year. Additionally, the market in Europe is also expected to show noteworthy growth on the account of growing cases of diseases such as bladder overactivity and Parkinson’s disease, among others. Alternatively, the market in the Asia Pacific is also expected to show generous growth over the forecast period on the back of the establishment of research and development centers along with developing healthcare infrastructure. Moreover, the growing setup of production units in developing countries such as India, Korea, and others is expected to drive the growth of the market in the region.
Market Segmentation
Our in-depth analysis of the global anticholinergic drugs market includes the following segments:
By Product Type
-
Natural
-
Semi-Synthetic Compound
-
Synthetic Compound
By Route of Administration
-
Parenteral
-
Topical
-
Oral
By Application
-
Muscle Spasm
-
Parkinson’s Disease
-
Irritable Bowel Syndrome
-
Chronic Obstructive Pulmonary Disease
-
Overactive Bladder
By Channel of Distribution
-
Hospitals
-
Retail Pharmacies
-
Online Pharmacies
Growth Drivers and Challenges Impacting the Growth of the Global Anticholinergic Drugs Market
Growth Drivers
-
Rising geriatric population
-
Growing prevalence of chronic illness such as neurological disorder
-
Investment in the field of life science
-
Incessant development in healthcare infrastructure
Challenges
-
Side effects caused by the drugs
-
Restrictions imposed by government on the use of drugs
Key Companies Dominating the Global Anticholinergic Drugs Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global anticholinergic drugs market that are included in our report are Pfizer Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd., Sanofi, GlaxoSmithKline plc., Novartis AG, Johnson & Johnson Services, Inc., Viatris Inc., Astellas Pharma Inc., and Boehringer Ingelheim International GmbH among others.
Latest Developments in the Global Anticholinergic Drugs Market:
-
01 December 2021: Astellas Pharma Inc. announced an option and license agreement with Dyno Therapeutics, Inc. main agenda of the agreement is to use Dyno’s “CapsidMap” platform in order to develop a next-generation adeno-associated virus (AAV) vectors for gene therapy targeting skeletal and cardiac muscle.
-
07 March 2022: Teva Pharmaceuticals Industries Ltd. announced the launch of lenalidomide capsules called “Revlimid”. The capsules will be used for treating multiple myeloma, myelodysplastic syndromes, and mantel cell lymphoma.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goals.
- Pfizer Inc.
- AbbVie Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi
- GlaxoSmithKline plc.
- Novartis AG
- Johnson & Johnson ServicesInc.
- Viatris Inc.
- Astellas Pharma Inc.
- Boehringer Ingelheim International GmbH
Related Reports
Proof of Quality & Reliability
